Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
T cell activation is insufficient to drive SIV disease progression
Cristian Apetrei, Thaidra Gaufin, Egidio Brocca-Cofano, Ranjit Sivanandham, Paola Sette, Tianyu He, Sindhuja Sivanandham, Natalie Martinez Sosa, Kathryn J. Martin, Kevin D. Raehtz, Adam J. Kleinman, Audrey Valentine, Noah Krampe, Rajeev Gautam, Andrew A. Lackner, Alan L. Landay, Ruy M. Ribeiro, Ivona Pandrea
Cristian Apetrei, Thaidra Gaufin, Egidio Brocca-Cofano, Ranjit Sivanandham, Paola Sette, Tianyu He, Sindhuja Sivanandham, Natalie Martinez Sosa, Kathryn J. Martin, Kevin D. Raehtz, Adam J. Kleinman, Audrey Valentine, Noah Krampe, Rajeev Gautam, Andrew A. Lackner, Alan L. Landay, Ruy M. Ribeiro, Ivona Pandrea
View: Text | PDF
Research Article AIDS/HIV Infectious disease

T cell activation is insufficient to drive SIV disease progression

  • Text
  • PDF
Abstract

Resolution of T cell activation and inflammation is a key determinant of the lack of SIV disease progression in African green monkeys (AGMs). Although frequently considered together, T cell activation occurs in response to viral stimulation of acquired immunity, while inflammation reflects innate immune responses to mucosal injury. We dissociated T cell activation from inflammation through regulatory T cell (Treg) depletion with Ontak (interleukin-2 coupled with diphtheria toxin) during early SIV infection of AGMs. This intervention abolished control of T cell immune activation beyond the transition from acute to chronic infection. Ontak had no effect on gut barrier integrity, microbial translocation, inflammation, and hypercoagulation, despite increasing T cell activation. Ontak administration increased macrophage counts yet decreased their activation. Persistent T cell activation influenced SIV pathogenesis, shifting the ramp-up in viral replication to earlier time points, prolonging the high levels of replication, and delaying CD4+ T cell restoration yet without any clinical or biological sign of disease progression in Treg-depleted AGMs. Thus, by inducing T cell activation without damaging mucosal barrier integrity, we showed that systemic T cell activation per se is not sufficient to drive disease progression, which suggests that control of systemic inflammation (likely through maintenance of gut integrity) is the key determinant of lack of disease progression in natural hosts of SIVs.

Authors

Cristian Apetrei, Thaidra Gaufin, Egidio Brocca-Cofano, Ranjit Sivanandham, Paola Sette, Tianyu He, Sindhuja Sivanandham, Natalie Martinez Sosa, Kathryn J. Martin, Kevin D. Raehtz, Adam J. Kleinman, Audrey Valentine, Noah Krampe, Rajeev Gautam, Andrew A. Lackner, Alan L. Landay, Ruy M. Ribeiro, Ivona Pandrea

×

Figure 1

Ontak administration to SIV-infected AGMs depletes Tregs.

Options: View larger image (or click on image) Download as PowerPoint
Ontak administration to SIV-infected AGMs depletes Tregs.
(A) Comparison...
(A) Comparison between CD25hiCD4+ T cell dynamics in acutely SIV-infected AGMs receiving Ontak (n = 4, red) and untreated controls (n = 5, gray). (B) Comparison between FoxP3+CD4+ T cell dynamics in acutely SIV-infected AGMs receiving Ontak (n = 4, red) and untreated controls (n = 5, gray). Shown are both the individual levels in treated versus untreated AGMs (left panels) and the average values for each group and standard error of means (right panels). Time points of Ontak treatment initiation (–2, 32, and 53 dpi) are marked by red arrows. Treg depletion in the lymph nodes (LNs) (left panels) and intestinal biopsies (right panels) after Ontak administration, as illustrated by the dynamics of the (C) CD25hiCD4+ T cells and (D) FoxP3+CD4+ T cells. (E) Flow cytometry data were validated by immunohistochemistry, showing a trend for FoxP3+ cell depletion in the LNs of the Ontak-treated AGMs compared with controls. Representative images (original magnification, 50×) of the LNs collected prior to infection, during the acute infection, at the setpoint (42 dpi), and during the chronic infection (166 dpi) and stained for FoxP3 (brown) in treated AGMs (n = 4) versus controls (n = 4). Quantification of the percentage area of the LNs positive for FoxP3.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts